Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

ABSTRACT:

Introduction

Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe sepsis and multiple organ systems failing.

Methods

This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control) for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate audit of DrotAA infusions. Re-admissions to critical ca

SUBMITTER: Sadique MZ 

PROVIDER: S-EPMC3334774 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature